Purdue Pharma announced today that it acquired SpineThera and a dexamethasone epidural product designed to treat low back pain.
SpineThera’s SX600 therapy features tiny, biodegradable microspheres which enable sustained-release of dexamethasone.
“We are pleased to partner with SpineThera to support further development of its novel steroid product for epidural injection for patients who suffer from low back pain,” Dr. Craig Landau, president & CEO of Purdue Pharma, said in prepared remarks. “We are committed to alleviating pain through new and innovative non-opioid medicines. SX600 represents an exciting opportunity to meet this important medical need and advance our mission.”
“We look forward to developing this important future product with the financial support of Purdue,” Jeff Missling, CEO of SpineThera, added. “Their expertise in pain management is critical as we embark on this meaningful collaboration.”
SpineThera plans to assess the safety and tolerability of SX600 as part of a clinical development program in 2019.